期刊文献+

一线化疗对肺癌二线多西紫杉醇有效率的影响

下载PDF
导出
摘要 目的评价一线化疗方案(含紫杉醇与不含紫杉醇)对晚期非小细胞肺癌二线多西紫杉醇治疗有效率的影响。方法回顾性分析晚期非小细胞肺癌患者接受单药多西紫杉醇二线治疗的临床资料,按一线化疗方案的不同分为含紫杉醇组与不含紫杉醇组,比较两组之间临床基线特征以及二线化疗有效率的差异。并进一步在Pubmed数据库检索多西紫杉醇二线治疗的Ⅱ/Ⅲ期随机对照临床试验进行比较研究。结果 53例患者入组,多西紫杉醇二线化疗总体有效率为17%(95%CI:14%~20%)。一线化疗方案含紫杉醇组患者27例,不含紫杉醇组26例,两组患者的年龄、性别、ECOG评分、病理类型、分期、一线化疗疗效等均未见显著性差异,两组多西紫杉醇二线化疗有效率为:7.4%(95%CI:1%~24%)VS 26.9%(95%CI:12%~48%),P=0.076。共7篇文献纳入分析,不同一线化疗方案(含与不含紫杉醇)对二线多西紫杉醇有效率均未见显著性影响。结论接受不同一线化疗方案(含紫杉醇与不含紫杉醇)的晚期非小细胞肺癌患者,二线多西紫杉醇有效率无显著性差别。
出处 《海峡药学》 2012年第10期131-133,共3页 Strait Pharmaceutical Journal
  • 相关文献

参考文献11

  • 1Hanna NH, Sheperd FA, Fossella FV, et al.Randomized phase III study of pemetrexed versus docetaxel in patients with non-small cell lung cancer previously treated with chemotherapy (J).J Ciin Oncol 2004;22:1589-1597.
  • 2Fossella FV, DeVore R,Kerr RN, et al.Randomized phase III trial ofdocetaxel versus vinorelbine or ifosfamide in patients with advancednon-small cell lung cancer previously treated with platinum-containingchemotherapy regimens.The TAX 320 Non-Small Cell Lung CancerStudy Group ⑴.J Clin Oncol 2000; 18 : 2354-2362.
  • 3Fossella FV, DeVore R, Kerr RN, et al. Randomized phase III trial ofdocetaxel versus vinorelbine or ifosfamide in patients with advancednon-small-cell lung cancer previously treated with platinum- containingchemotherapy regimens. The TAX 320 Non-Small Cell Lung CancerStudy Group.].J Clin Oncol.2000:18(12):2354-62.
  • 4Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trialof pemetrexed versus docetaxel in patients with non-small-cell lungcancer previously treated with chemotherapyQJ . J Clin Oncol.2004;22(9):1589-97.
  • 5Pectasides D, Pectasides M, Farmakis D. et al.Comparison of docetax-el and docetaxel- irinotecan combination as second-line chemotherapyin advanced non-small-cell lung cancer: a randomized phase II trial[J].Ann Oncol.2005il6(2):294-9.
  • 6Schuette W, Nagel S, Blankenburg T, et al. Phase III study of second-line chemotherapy for advanced non-small-cell lung cancer with week-ly compared with 3-weekly docetaxel(J).J Clin Oncol. 2005;23(33):8389-95.
  • 7Chen YM, Shih JF, Perng RP, et al. A randomized trial of differentdocetaxel schedules in non-small cell lung cancer patients who failedprevious platinum-based chemotherapy [Jj .Chest.2006; 129 (4):1031-8.
  • 8Kim ES, Hirsh V, Mok T, et al.Gefitinib vereus docetaxel in previous-ly treated non-small-cell lung cancer ( INTEREST): a randomisedphase ID trialQ).Lancet.2008,*372(9652):1809-18.
  • 9Pallis AG. Agelaki S, Agelidou A, et al. A randomized phase HI studyof the docetaxel/ carboplatin combination versus docetaxel single-agentas second line treatment for patients with advanced/ metastatic non-small cell lung cancer [J].BMC Cancer. 2010; 10 : 633..
  • 10Verweij J. Clavel M’ Chevalier B. Paclitaxel (Taxol)and docetaxel(Taxotere);not simply two of a kind (J} .Ann Oncol. 1994; 5 (6 ):495-505.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部